Clinical trials
Phase 3 Leiomyosarcoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Terminated | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 6 |
| Advenchen Laboratories, LLC | 1 |
| Alliance for Clinical Trials in Oncology | 1 |
| Children's Oncology Group | 1 |
| Eli Lilly and Company | 1 |
| Italian Sarcoma Group | 1 |
| Janssen Research & Development, LLC | 1 |
| PharmaMar | 1 |
| Polaris Group | 1 |
| Sheffield Teaching Hospitals NHS Foundation Trust | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leiomyosarcoma | 16 |
| Sarcoma | 13 |
| Liposarcoma | 12 |
| Sarcoma, Synovial | 10 |
| Histiocytoma, Malignant Fibrous | 9 |
| Fibrosarcoma | 8 |
| Hemangiosarcoma | 8 |
| Neurofibrosarcoma | 8 |
| Sarcoma, Alveolar Soft Part | 5 |
| Rhabdomyosarcoma | 4 |
Trials
Showing 76 to 16 of 16. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.